Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Estrella Immunopharma ( (ESLA) ) has issued an announcement.
On January 7, 2026, Estrella Immunopharma, Inc. received notice from Nasdaq that it is out of compliance with listing requirements for failing to hold an annual shareholders’ meeting within the prescribed timeframe. The company has 45 days to submit a compliance plan, is preparing to convene an annual meeting in April 2026, and will consult with Nasdaq on whether that meeting will be sufficient to restore compliance, while the notification has no immediate impact on the listing or trading of its securities and creates uncertainty over its continued Nasdaq standing if a plan is not accepted.
The most recent analyst rating on (ESLA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Estrella Immunopharma stock, see the ESLA Stock Forecast page.
More about Estrella Immunopharma
Average Trading Volume: 271,065
Technical Sentiment Signal: Sell
Current Market Cap: $50.44M
For a thorough assessment of ESLA stock, go to TipRanks’ Stock Analysis page.